Bextra heart attack Philadelphia

Bextra or Valdecoxib

Bextra® heart attack Philadelphia. Speak to your doctor right away about alternatives to this drug.

Withdrawal

On April 7, 2005 the FDA announced that it has asked Pfizer, Inc. to withdraw Bextra from the market "because the overall risk versus benefit profile for the drug is unfavorable."

Side Effects for Bextra or Valdecoxib include the following:

Potential for increased risk of cardiovascular events
Gastrointestinal bleeding
Serious skin reactions, some resulting in death.

What is Bextra?

Bextra® is a non-steroidal anti-inflammatory drug (NSAIDs), known as a COX-2 selective agent. It is prescribed for inflammation and pain from arthritis or menstrual cramping. Other drugs in this class include Celebrex® and Vioxx®. Bextra® and Celebrex® are both marketed by Pharmacia Corporation and Pfizer and Vioxx® is manufactured by Merck. Doctors switched patients from Vioxx® to Bextra® when Merck voluntarily removed it from the market due studies showing an increased risk for heart attack and stroke.

To read the FDA's announcement withdrawing Bextra
For a free case evaluation from a Philadelphia attorney, click here: http://www.lawforum.net/areas/bextra/pennsylvania/philadelphia/
Munley, Munley & Cartwright, P.C. is a Pennsylvania law office which has breaking news and information about this lawsuit http://www.munley.com/drugs/bextra.html
Click here to read the FDA questions and answers about strengthened warnings on Bextra® boxes http://www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm
To report any unexpected adverse or serious events associated with the use of Bextra® contact the FDA MedWatch program at: 1-800-FDA-1088 or on the Internet at http://www.fda.gov/medwatch/index.html

bextra site map

Autism Education Materials!